These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 33441754)

  • 1. Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients.
    Imahashi M; Ode H; Kobayashi A; Nemoto M; Matsuda M; Hashiba C; Hamano A; Nakata Y; Mori M; Seko K; Nakahata M; Kogure A; Tanaka Y; Sugiura W; Yokomaku Y; Iwatani Y
    Sci Rep; 2021 Jan; 11(1):960. PubMed ID: 33441754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine.
    Ray S; Narayanan A; Giske CG; Neogi U; Sönnerborg A; Nowak P
    ACS Infect Dis; 2021 May; 7(5):1104-1115. PubMed ID: 33346662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the intestinal microbiota in MSM with HIV infection.
    Fu Y; Ke S; Tang G; Guo Q; Guo Q; Wang Z; Leng R; Fan Y
    BMC Microbiol; 2024 Jun; 24(1):192. PubMed ID: 38831399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients.
    Villanueva-Millán MJ; Pérez-Matute P; Recio-Fernández E; Lezana Rosales JM; Oteo JA
    J Int AIDS Soc; 2017 Mar; 20(1):21526. PubMed ID: 28362071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal Bacterial Communities in treated HIV infected individuals on two antiretroviral regimens.
    Pinto-Cardoso S; Lozupone C; Briceño O; Alva-Hernández S; Téllez N; Adriana A; Murakami-Ogasawara A; Reyes-Terán G
    Sci Rep; 2017 Mar; 7():43741. PubMed ID: 28262770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation.
    Ishizaka A; Koga M; Mizutani T; Parbie PK; Prawisuda D; Yusa N; Sedohara A; Kikuchi T; Ikeuchi K; Adachi E; Koibuchi T; Furukawa Y; Tojo A; Imoto S; Suzuki Y; Tsutsumi T; Kiyono H; Matano T; Yotsuyanagi H
    Microbiol Spectr; 2021 Sep; 9(1):e0070821. PubMed ID: 34378948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy.
    Lewy T; Hong BY; Weiser B; Burger H; Tremain A; Weinstock G; Anastos K; George MD
    AIDS Res Hum Retroviruses; 2019 Mar; 35(3):276-286. PubMed ID: 29808701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in the gut microbiota of patients with acquired immune deficiency syndrome.
    Zhou Y; Ou Z; Tang X; Zhou Y; Xu H; Wang X; Li K; He J; Du Y; Wang H; Chen Y; Nie Y
    J Cell Mol Med; 2018 Apr; 22(4):2263-2271. PubMed ID: 29411528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Composition of Gut Microbiota of Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection Taking Antiretroviral Therapy in Zimbabwe.
    Flygel TT; Sovershaeva E; Claassen-Weitz S; Hjerde E; Mwaikono KS; Odland JØ; Ferrand RA; Mchugh G; Gutteberg TJ; Nicol MP; Cavanagh JP; Flægstad T;
    J Infect Dis; 2020 Jan; 221(3):483-492. PubMed ID: 31549151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy.
    Annavajhala MK; Khan SD; Sullivan SB; Shah J; Pass L; Kister K; Kunen H; Chiang V; Monnot GC; Ricupero CL; Mazur RA; Gordon P; de Jong A; Wadhwa S; Yin MT; Demmer RT; Uhlemann AC
    mSphere; 2020 Feb; 5(1):. PubMed ID: 32024712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
    Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
    J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Two-Faced Gut Microbiome: Butyrogenic and Proinflammatory Bacteria Predominate in the Intestinal Milieu of People Living with HIV from Western Mexico.
    Baltazar-Díaz TA; Andrade-Villanueva JF; Sánchez-Álvarez P; Amador-Lara F; Holguín-Aguirre T; Sánchez-Reyes K; Álvarez-Zavala M; López-Roa RI; Bueno-Topete MR; González-Hernández LA
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan.
    Ruzicka DJ; Kamakura M; Kuroishi N; Oshima N; Yamatani M; Yi J; Crawford B; Tsukada K; Oka S
    PLoS One; 2022; 17(6):e0269779. PubMed ID: 35700215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
    Karade S; Sen S; Sashindran VK
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes.
    Ancona G; Merlini E; Tincati C; Barassi A; Calcagno A; Augello M; Bono V; Bai F; Cannizzo ES; d'Arminio Monforte A; Marchetti G
    Front Immunol; 2021; 12():639291. PubMed ID: 33717191
    [No Abstract]   [Full Text] [Related]  

  • 19. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.